Status:
TERMINATED
Neurofeedback In Treatment Resistant Depression
Lead Sponsor:
Yeungnam University Hospital
Conditions:
Depression
Neurofeedback
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The investigators evaluate the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD). TRD patients...
Detailed Description
Major depressive disorder (MDD) is a severely disabling disorder resulting in the deterioration of daily function and lowering quality of life. The lifetime prevalence of depression is 10-15%, and the...
Eligibility Criteria
Inclusion
- Diagosis with MDD according to the DSM-IV-TR criteria for MDD, and especially treatment-resistant MDD (Hamilton Rating Scale for Depression \[HAM-D\] score ⩾14) despite adequate antidepressant therapy)
Exclusion
- Psychosis
- Bipolar disorder
- Brain injury
- Clinically diagnosed neurological disorder
- Convulsive disorder
- Pregnancy
Key Trial Info
Start Date :
June 27 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 8 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04078438
Start Date
June 27 2014
End Date
February 8 2020
Last Update
July 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yeungnam University Hospital
Daegu, South Korea, 42415